Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced the addition of a significant new hospital account in the USA.
The new account is a 600 bed teaching hospital which initially plans to treat around 40 patients per month within its surgical enhanced recovery programmes. After the hospital’s positive clinical evaluation of ODM was completed in the first half of 2015, implementation was delayed pending a hospital system merger. As a result of the combination, there are now ten further hospitals in the enlarged system. The procurement agreement covers the whole system, providing scope for relatively rapid conversion of future clinical acceptance of ODM into incremental revenues.
Ewan Phillips, Deltex Medical Group plc Chief Executive, commented: “We are delighted that this new account has now come through the pipeline. It is the sixth major hospital in our Mid-Atlantic sales territory and should further support the growth in one of our top-performing territories, where 2017 first half revenues were over 50% ahead of the first half of 2016.”
